Skip to content
Peptigraph home

SYNCHRONIZE™-1: Survodutide Phase 3 trial (NCT06066515)

A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity Without Type 2 Diabetes

Registry record checked

At a glance

Phase
Phase 3
Status
Completed
Enrolment
726
actual
Start
25 Nov 2023 (actual)
Primary completion
2 Dec 2025 (actual)
Sponsor
Boehringer Ingelheim
Design

Arms and doses

NCT06066515 study arms
ArmTypeInterventionsDescription
Survodutide 3.6 mgExperimentalCombination Product: survodutideNot stated
Survodutide 6.0 mgExperimentalCombination Product: survodutideNot stated
PlaceboPlacebo comparatorCombination Product: PlaceboNot stated
Endpoints

Primary endpoint

NCT06066515 primary outcomes
MeasureTime frame
Percentage change in body weight from baseline to Week 76Baseline and at Week 76
Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76Baseline and at Week 76
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT06066515 secondary outcomes
MeasureTime frame
Achievement of body weight reduction ≥10% (yes/no) from baseline to Week 76Baseline and at Week 76
Achievement of body weight reduction ≥15% (yes/no) from baseline to Week 76Baseline and at Week 76
Achievement of body weight reduction ≥20% (yes/no) from baseline to Week 76Baseline and at Week 76
Absolute change from baseline to Week 76 in body weight (kg)Baseline and Week 76
Absolute change from baseline to Week 76 in waist circumference (cm)Baseline and at Week 76
Absolute change from baseline to Week 76 in systolic blood pressure (SBP) (mmHg)Baseline and at Week 76
Absolute change from baseline to Week 76 in "Capacity to Resist" domain score of the Eating Behaviour patient reported outcome (PRO)Baseline and at Week 76
Absolute change from baseline to Week 76 in Eating Behaviour PRO total scoreBaseline and at Week 76
Absolute change from baseline to Week 76 in body mass index (BMI) (kg/m2)Baseline and at Week 76
Absolute change from baseline to Week 76 in diastolic blood pressure (DBP) (mmHg)Baseline and at Week 76
Absolute change from baseline to Week 76 in glycosylated haemoglobin A1c (HbA1c) (%)Baseline and at Week 76
Absolute change from baseline to Week 76 in HbA1c (mmol/mol)Baseline and at Week 76
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

SYNCHRONIZE-1 in adults with obesity

Adults with a BMI of 30 or higher, or 27 or higher with a complication, were randomised 1:1:1 to survodutide up to 3.6 mg, up to 6.0 mg, or placebo.[2]

At week 76 weight changed by -12.2% (3.6 mg), -13.0% (6.0 mg) and -5.4% (placebo), with at least 5% loss in 72.6%, 71.9% and 46.3%.[2]

Gastrointestinal events occurred in 80.9% of the 3.6 mg group, 89.7% of the 6.0 mg group and 47.9% of the placebo group.[2]

No deaths were reported.[2]

Sources

  1. 1A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity Without Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
  2. 2Survodutide Once Weekly for the Treatment of Adults with Obesity.The New England journal of medicine · 2026PMID 42253238Accessed 2 Oct 2026

Found an error? Report a correction.